Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects

Hypertension

Volumn 28, Issue 4, 1996, Pages 647-651

  Chan, Paul ^a,e   Tomlinson, Brian ^d   Lee, Ching Bing ^b   Pan, Wen Harn ^c   Lee, Ying Shiung ^b  

^a ACADEMIA SINICA   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e Taipei Municipal Chung Hsiao Hospital   (Taiwan)

Author keywords

cholesterol; hydroxymethylglutaryl CoA reductases; hyperinsulinism; pravastatin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PRAVASTATIN; TRIACYLGLYCEROL;

AGED; AGING; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL IMPAIRMENT;

EID: 0029818679     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.4.647     Document Type: Article

References (29)

1. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, Grundy SM, Rakita L, Robertson RM, Weisfeldt ML, Cleeman JI. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 1990;81:1721-1733.
2. Pekkanen J, Nissinen A, Puska P, Punsar S, Karvonen MJ. Risk factors and 25 year risk of coronary heart disease in male population with a high incidence of the disease: the Finnish cohorts of the Seven Countries Study. Br Med J. 1989;299:81-85.
3. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wenworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet. 1986;1:933-936.
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
5. Pederson TR. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
6. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
7. Swislocki AL, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens. 1989;2:419-423.
8. Berglund G, Larsson B, Andersson O, Larsson O, Svardsudd K, Bjorntorp P, Wilhelmsen L. Body composition and glucose metabolism in hypertensive middle-aged men. Acta Med Scand. 1976; 200:163-169.
9. Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven G. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320:702-706.
10. Welbon TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes Care. 1979;2:154-160.
11. Ducimetiere P, Eschwege R, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980;19:205-210.
12. Pyorala K, Uusitupa M, Laakso M, Siitonen O, Niskanen L, Ronnemaa T. Macrovascular complications in relation to hyperinsulinemia in non-insulin dependent diabetes mellitus. Diabete Metab. 1987;13:345-349.
13. Gidez LI, Miller GJ, Burstein M. Separation and quantification of subclasses of human high-density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982;23:1206-1223.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J. 1990;300:230-235.
16. Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci Am. 1984;251:58-66.
17. Blum CB. Comparison of properties of four inhibitors of 3-hydroxyl-3 methylglutaryl-coenzyme A reductase. Am J Cardiol. 1994;73: 3D-11D.
18. Celis H, Lijnen P, Fagard R, Staessen J, Thijs L, Amery A. Efficacy and safety of pravastatin in hypertensive hypercholesterolemic patients on antihypertensive drug therapy. J Hum Hypertens. 1994; 8:525-530.
19. Chan P, Lee CB, Lin TH, Ko JT, Pan WH, Lee YH. The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. Am J Hypertens. 1995;8:1099-1104.
20. Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, Higgins J, Downton M, Franklin FA, Nash DT, Gould AL, Langendorfer A. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, IV: additional perspectives on the tolerability of lovastatin. Am J Med. 1991;91(suppl 1B):25S-30S.
21. Morgan T, Anderson A, McDonald P, Hopper J, Macaskill G. Simvastatin in the treatment of hypercholesterolemia in patients with essential hypertension. J Hypertens. 1990;8(suppl 1):25S-32S.
22. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Am Heart J. 1991;121:696-701.
23. Pollare T, Lithell H, Bern C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
24. McTavish D, Sorkin EM. Pravastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs. 1991;42:65-89.
25. Jungnickel PW, Cantral KA, Maloley PA. Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin Pharmacy. 1992; 11:677-689.
26. Kashyap ML. Cardiovascular disease in the elderly: current considerations. Am J Cardiol. 1989;63:3H-4H.
27. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern Med. 1990;112:780-792.
28. Turpeinen O, Karvonen MJ, Pekkarinen M, Miettenen M, Elsusou R, Paavilainen E. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study. Int J Epidemiol. 1979;8:99-118.
29. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-1477.